The Clinical Efficacy Evaluation of the KHA-200 Hemoperfusion Device in the Treatment of End-Stage Renal Disease Patients Undergoing Blood Purification Therapy
Employing the KHA-200 hemoperfusion device in tandem with hemodialysis excels in removing blood phosphorus and certain medium-sized uremic toxins, including PTH, IL-6, β2-MG, and Hcy, surpassing the performance of conventional hemodialysis.
Authors
- Qing Yang (ORCID: https://orcid.org/0000-0003-4844-4690)
- Dunlu Yuan
- Min Guo (ORCID: https://orcid.org/0000-0002-7489-548X)
- Qing Li (ORCID: https://orcid.org/0000-0001-5452-2734)
- Jingjing Huang (ORCID: https://orcid.org/0000-0003-0522-9923)
- Guoquan Liu (ORCID: https://orcid.org/0000-0003-0680-4811)
- Zhu Zhou
Institutions
- Kunming Medical University (CN)
- First Affiliated Hospital of Kunming Medical University (CN)
Publication Details
- Journal
- Kidney Diseases
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1159/000545262
- Citations
- 1
- Primary Topic
- Dialysis and Renal Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 1.43